NCT00728780View on ClinicalTrials.gov

Study to Compare the Bioavailability of ABT-335 and Rosuvastatin From ABT-143 Capsules Relative to That From Co-administration of ABT-335 and Rosuvastatin for the 5/45mg Dosage Form.

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

August 31, 2008

Primary Completion Date

September 30, 2008

Conditions
Adverse EventsPharmacokinetic Variables
Interventions
DRUG

ABT-143

once

DRUG

ABT-335 and rosuvastatin

once

Trial Locations (1)

47710

Site Reference ID/Investigator# 11101, Evansville

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
lead

AstraZeneca

INDUSTRY

NCT00728780 - Study to Compare the Bioavailability of ABT-335 and Rosuvastatin From ABT-143 Capsules Relative to That From Co-administration of ABT-335 and Rosuvastatin for the 5/45mg Dosage Form. | Biotech Hunter | Biotech Hunter